# US 9,750,746 B2 · ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,746 B2
- Document ID: US9750746B2
- Status: Granted
- Kind: B2
- Application number: 13/940,352
- Filed: 2013-07-12
- Published: 2014-10-02
- Granted: 2017-09-05
- Earliest claimed: 2013-03-28
- Assignees: Anavex Life Sciences Corp.
- Applicants: Anavex Life Sciences Corp
- Inventors: Alexandre Vamvakides; Tangui Maurice
- Web page: https://patentgrep.com/patent/US9750746B2

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 307/14: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.

## Claims

### Claim 1

A dosage form comprising a therapeutically neuroprotective amount of A2-73 of about 0.1 mg/kg and a neuroprotective amount of the cooperating acetylcholinesterase inhibitor donepezil of about 0.25 mg/kg.

### Claim 2

The dosage form of a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of the cooperating acetylcholinesterase inhibitor donepezil wherein said therapeutically neuroprotective amounts of A2-73: donepezil are present at a ratio of about 2:5 by weight.